Clinical Trials
3 trialsNCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT05652283 2024-11-27
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Active not recruiting
NCT06437353 2024-11-27
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Recruiting